In a report released on March 7, Roger Song from Jefferies maintained a Buy rating on United Therapeutics (UTHR – Research Report), with a price target of $432.00.
Roger Song has given his Buy rating due to a combination of factors that suggest a positive outlook for United Therapeutics. Despite a recent decline in stock price, Song does not see any fundamental changes in the company’s commercial franchise, pipeline development, or overall business outlook. The company anticipates double-digit growth starting in 2025, supported by the expected launch of new programs such as the Phase 3 IPF trial and the xenotransplant initiative, both of which could significantly bolster midterm revenue.
Furthermore, Song notes that while there is potential competition from products like Yutrepia and Winrevair, these are not expected to substantially impact United Therapeutics’ market position. The company has strategies in place to mitigate competitive pressures, including preemptive pricing adjustments and a focus on volume over price. Additionally, the ongoing development in IPF and xenotransplant programs is expected to provide meaningful updates and potential upside in the near term, reinforcing the Buy recommendation.
Song covers the Healthcare sector, focusing on stocks such as Altimmune, United Therapeutics, and Kura Oncology. According to TipRanks, Song has an average return of -23.3% and a 22.78% success rate on recommended stocks.
In another report released on February 28, Argus Research also maintained a Buy rating on the stock with a $375.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com